How it works

Rozanolixizumab is a type of medicine known as an FcRn inhibitor. The FcRn is a receptor found on different cell types and one of its jobs is to extend the presence of a type of antibody called IgG. It is the most common type of antibody found in blood circulation. IgG is also responsible for triggering the immune system to disrupt communication between nerve and muscle cells like we see happening in MG. By binding the FcRn, rozanolixizumab can reduce the length of time IgG can circulate in the blood and prevent this disruption in MG patients. Rozanolixizumab has been reported to work in patients with and acetylcholine receptor antibody-positive MG and MuSK antibody-positive MG.

How it is delivered

Rozanolixizumab can be administered subcutaneously via infusion pump.

When you have it

The infusion is administered once per week for six weeks.

Side effects

All new medicines can cause unwanted side effects. When starting rozanolixizumab, you may experience the following:

·        Headache

·        Diarrhoea

·        Nausea

If these symptoms persist, speak to your doctor. Please consult with your doctor for an extended list of possible side effects.

Related UK companies

UCB (developer) 

Treatments